Cargando…

Current therapeutics against HCV

Hepatitis C is a positive stranded enveloped RNA virus belonging to the Flaviviridae family. HCV infection leads to severe liver diseases, cirrhosis and hepatocellular carcinoma worldwide. Although treatments have been available for a while, due to its complexity and genetic diversity, only few are...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharjee, Chayan, Singh, Maitri, Das, Debisukti, Chaudhuri, Sujit, Mukhopadhyay, Aparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279913/
https://www.ncbi.nlm.nih.gov/pubmed/34307769
http://dx.doi.org/10.1007/s13337-021-00697-0
_version_ 1783722541995524096
author Bhattacharjee, Chayan
Singh, Maitri
Das, Debisukti
Chaudhuri, Sujit
Mukhopadhyay, Aparna
author_facet Bhattacharjee, Chayan
Singh, Maitri
Das, Debisukti
Chaudhuri, Sujit
Mukhopadhyay, Aparna
author_sort Bhattacharjee, Chayan
collection PubMed
description Hepatitis C is a positive stranded enveloped RNA virus belonging to the Flaviviridae family. HCV infection leads to severe liver diseases, cirrhosis and hepatocellular carcinoma worldwide. Although treatments have been available for a while, due to its complexity and genetic diversity, only few are reported to be effective against all HCV genotypes. Here, we review the HCV life cycle and its immunogenic potential and various mechanisms via which the virus interferes in the signalling process. A comprehensive overview of current anti-HCV therapeutics, such as, Direct Acting Antiviral (DAA) as well as Host Targeting Agents (HTA), along with their scope, known mechanism of action and limitations are presented. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13337-021-00697-0.
format Online
Article
Text
id pubmed-8279913
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-82799132021-07-19 Current therapeutics against HCV Bhattacharjee, Chayan Singh, Maitri Das, Debisukti Chaudhuri, Sujit Mukhopadhyay, Aparna Virusdisease Review Article Hepatitis C is a positive stranded enveloped RNA virus belonging to the Flaviviridae family. HCV infection leads to severe liver diseases, cirrhosis and hepatocellular carcinoma worldwide. Although treatments have been available for a while, due to its complexity and genetic diversity, only few are reported to be effective against all HCV genotypes. Here, we review the HCV life cycle and its immunogenic potential and various mechanisms via which the virus interferes in the signalling process. A comprehensive overview of current anti-HCV therapeutics, such as, Direct Acting Antiviral (DAA) as well as Host Targeting Agents (HTA), along with their scope, known mechanism of action and limitations are presented. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13337-021-00697-0. Springer India 2021-07-15 2021-06 /pmc/articles/PMC8279913/ /pubmed/34307769 http://dx.doi.org/10.1007/s13337-021-00697-0 Text en © Indian Virological Society 2021
spellingShingle Review Article
Bhattacharjee, Chayan
Singh, Maitri
Das, Debisukti
Chaudhuri, Sujit
Mukhopadhyay, Aparna
Current therapeutics against HCV
title Current therapeutics against HCV
title_full Current therapeutics against HCV
title_fullStr Current therapeutics against HCV
title_full_unstemmed Current therapeutics against HCV
title_short Current therapeutics against HCV
title_sort current therapeutics against hcv
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279913/
https://www.ncbi.nlm.nih.gov/pubmed/34307769
http://dx.doi.org/10.1007/s13337-021-00697-0
work_keys_str_mv AT bhattacharjeechayan currenttherapeuticsagainsthcv
AT singhmaitri currenttherapeuticsagainsthcv
AT dasdebisukti currenttherapeuticsagainsthcv
AT chaudhurisujit currenttherapeuticsagainsthcv
AT mukhopadhyayaparna currenttherapeuticsagainsthcv